TRUFFLE-CAPITAL
8.7.2021 08:02:05 CEST | Business Wire | Press release
Created by the private equity firm Truffle Capital and the research and consulting firm teknowlogy | CXP-PAC, the Truffle 100 2021 provides an overview of the French software industry by analyzing the activity of the top 100 companies in the sector during 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005107/en/
- This period was marked by several notable highlights: with a +6.6% increase, the growth in activity in the sector reached record highs, i.e. €11.6 billion; however, a record number of companies (33%) posted a fall in revenue.
- For the first time since 2013, the difference between the 50th and the 100th publishers decreased; but with 35% of the sector's revenue in 2020, the weighting of the company in first place continues to grow (+2 pts in 2020)
The Truffle 100 clearly shows that the anticipated market shock has not affected the whole software industry. Nevertheless, the companies have put forward a shared vision of the future of the market.
- The cloud is now considered by 92% of companies as the trend that will provide momentum in the sector over the coming years. This new trend, driven by the crisis, recorded a growth of +16 pts compared to the ranking published in 2020.
- In light of this situation, three-quarters of the companies plan to increase their workforce, and three-quarters also plan to ramp up their R&D projects.
Commenting on this 16th edition of Truffle 100, Cédric Ô, French Secretary of State for the Digital Economy, concluded: "In similar fashion to previous years, the development of the sector has been achieved by the long-standing efforts of its stakeholders and their capacity to anticipate the major technological breakthroughs which are, in the digital industry, more frequent and clearer to distinguish than in other industries ".
Bernard-Louis Roques, Managing Director and co-founder of Truffle Capital declared: "At a time when the ability to respond to events and the management of expertise proved vital, the French software industry played a civic role and created jobs on the domestic marke t".
Nadia Idrissi, Chairwoman of teknowlogy | CXP-PAC, added: "Highly topical themes such as the cloud, cybersecurity and the remote workplace have driven the market and allowed the majority of publishers, who are - on the whole - well prepared, to deliver revenue growth. [...] Companies using software solutions are picking up the pace of this forced march towards major digital transformation investments, and this also applies to industrial processes ".
The 16th edition of the Truffle 100 is available on the following website: https://www.truffle100.fr/
About Truffle Capital
Founded in 2001, Truffle Capital is an independent European venture capital company, specializing in life sciences (MedTech and Biotech) and breakthrough technologies in the IT sectors (FinTech and InsurTech). Truffle Capital’s mission is to support the creation and development of young innovative companies capable of becoming tomorrow’s leaders. The company is chaired by Patrick Kron and managed by Dr Philippe Pouletty and Bernard-Louis Roques, co-founders and General Managers. Truffle Capital manages €700 million in assets. Since its creation, it has raised nearly €1.1 billion and has supported over 75 companies in the digital technology and life sciences sectors. In 2019, Truffle Capital announced it had raised nearly €400 million in new institutional funds, including €140 million in Fintech/Insurtech.
Further information: www.truffle.com — Twitter: @trufflecapital
About teknowlogy Group
teknowlogy | CXP-PAC teknowlogy | CXP-PAC is the leading European independent analysis and consulting firm in the field of software, IT services and digital transformation. As a privileged partner of European user companies, it offers them assistance in defining their digital strategy, managing projects and reducing the risks linked to technological choices and their implementation.
Owing to its knowledge of market trends and user-company expectations, teknowlogy | CXP-PAC helps software publishers and ESNs to better establish, execute and promote their own strategy in line with market expectations and in anticipation of future needs.
Capitalizing on more than 40 years of experience, teknowlogy | CXP-PAC has a network of 50 experts based in Paris, Munich, Bucharest, and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005107/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom